Ken Frazier Joins Former Merck & Co Colleagues At Eikon Therapeutics

Becomes Start-Up’s First Independent Board Member

 
• By Andrew McConaghie

Frazier has answered the call from Roger Perlmutter, his former head of R&D at Merck, to help the mysterious new biotech develop its platform.

Eikon Therapeutics
Eikon Therapeutics's platform can track real-time movements of proteins in living cells in the service of novel drug discovery. • Source: Eikon Therapeutics (McConaghie, Andrew)

More from Business

More from Scrip